Tdap vaccine and pregnancy. Why is itimportant? Safety and efficacy of thevaccine

Descripción del Articulo

Pertussis (Bordetella pertussis) is a highly contagious respiratory disease that poses a significant threat to infants under six months of age, in whom clinical manifestations may be atypical and complications severe or fatal, including apnea, pneumonia, encephalopathy, and death. Despite the availa...

Descripción completa

Detalles Bibliográficos
Autor: Namizato Ikemiyashiro, Claudia Sofia
Formato: artículo
Fecha de Publicación:2025
Institución:Sociedad Peruana de Obstetricia y Ginecología
Repositorio:Revista Peruana de Ginecología y Obstetricia
Lenguaje:español
inglés
OAI Identifier:oai:ginecologiayobstetricia.pe:article/2773
Enlace del recurso:https://ginecologiayobstetricia.pe/index.php/RPGO/article/view/2773
Nivel de acceso:acceso abierto
Materia:Whooping cough
Pertussis
Bordetella pertussis
Tdap vaccine
Maternal vaccination
Tos ferina
Vacuna Tdap
Vacunación en el embarazo
id REVSPOG_1c3f8b002eef956a043662ea164f69e3
oai_identifier_str oai:ginecologiayobstetricia.pe:article/2773
network_acronym_str REVSPOG
network_name_str Revista Peruana de Ginecología y Obstetricia
repository_id_str .
dc.title.none.fl_str_mv Tdap vaccine and pregnancy. Why is itimportant? Safety and efficacy of thevaccine
Vacuna Tdap y embarazo. ¿Porque es importante su administración?. Seguridad y eficacia de la vacuna
title Tdap vaccine and pregnancy. Why is itimportant? Safety and efficacy of thevaccine
spellingShingle Tdap vaccine and pregnancy. Why is itimportant? Safety and efficacy of thevaccine
Namizato Ikemiyashiro, Claudia Sofia
Whooping cough
Pertussis
Bordetella pertussis
Tdap vaccine
Maternal vaccination
Tos ferina
Bordetella pertussis
Vacuna Tdap
Vacunación en el embarazo
title_short Tdap vaccine and pregnancy. Why is itimportant? Safety and efficacy of thevaccine
title_full Tdap vaccine and pregnancy. Why is itimportant? Safety and efficacy of thevaccine
title_fullStr Tdap vaccine and pregnancy. Why is itimportant? Safety and efficacy of thevaccine
title_full_unstemmed Tdap vaccine and pregnancy. Why is itimportant? Safety and efficacy of thevaccine
title_sort Tdap vaccine and pregnancy. Why is itimportant? Safety and efficacy of thevaccine
dc.creator.none.fl_str_mv Namizato Ikemiyashiro, Claudia Sofia
Namizato Ikemiyashiro, Claudia Sofia
author Namizato Ikemiyashiro, Claudia Sofia
author_facet Namizato Ikemiyashiro, Claudia Sofia
author_role author
dc.subject.none.fl_str_mv Whooping cough
Pertussis
Bordetella pertussis
Tdap vaccine
Maternal vaccination
Tos ferina
Bordetella pertussis
Vacuna Tdap
Vacunación en el embarazo
topic Whooping cough
Pertussis
Bordetella pertussis
Tdap vaccine
Maternal vaccination
Tos ferina
Bordetella pertussis
Vacuna Tdap
Vacunación en el embarazo
description Pertussis (Bordetella pertussis) is a highly contagious respiratory disease that poses a significant threat to infants under six months of age, in whom clinical manifestations may be atypical and complications severe or fatal, including apnea, pneumonia, encephalopathy, and death. Despite the availability of effective vaccines for decades, pertussis continues to be a public health problem, with recurring epidemic cycles.Since the childhood vaccination schedule is not completed until six months of age, newborns and infants remain vulnerable. Tdap vaccination during pregnancy has been shown to be an effective and safe strategy for preventing the disease at this stage. Administering the vaccine between 20 and 36 weeks of gestation—preferably at least two weeks before delivery—ensures adequate transplacental transfer of antibodies, conferring passive protection to the newborn. Numerous observationalstudies and meta-analyses have shown significant reductions in hospitalizations, severe illness, and mortality in infants born to vaccinated mothers. Likewise, no significant maternal, obstetric, or neonatal risks have been observed. Nor has maternal vaccination been shown to clinically interfere with the infant's immune response after receiving their own vaccination schedule. Vaccination coverage among pregnant women in Peru is still suboptimal, highlighting the need for health personnel to commit to recommending and implementing this intervention in every pregnancy as an integral part of prenatal care.
publishDate 2025
dc.date.none.fl_str_mv 2025-11-13
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://ginecologiayobstetricia.pe/index.php/RPGO/article/view/2773
10.31403/rpgo.v71i2790
url https://ginecologiayobstetricia.pe/index.php/RPGO/article/view/2773
identifier_str_mv 10.31403/rpgo.v71i2790
dc.language.none.fl_str_mv spa
eng
language spa
eng
dc.relation.none.fl_str_mv https://ginecologiayobstetricia.pe/index.php/RPGO/article/view/2773/3053
https://ginecologiayobstetricia.pe/index.php/RPGO/article/view/2773/3054
dc.rights.none.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Sociedad Peruana de Obstetricia y Ginecología
publisher.none.fl_str_mv Sociedad Peruana de Obstetricia y Ginecología
dc.source.none.fl_str_mv The Peruvian Journal of Gynecology and Obstetrics ; Vol. 71 No. 2 (2025)
Revista Peruana de Ginecología y Obstetricia; Vol. 71 Núm. 2 (2025)
2304-5132
2304-5124
10.31403/rpgo.v71i
reponame:Revista Peruana de Ginecología y Obstetricia
instname:Sociedad Peruana de Obstetricia y Ginecología
instacron:SPOG
instname_str Sociedad Peruana de Obstetricia y Ginecología
instacron_str SPOG
institution SPOG
reponame_str Revista Peruana de Ginecología y Obstetricia
collection Revista Peruana de Ginecología y Obstetricia
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1868078739572654080
spelling Tdap vaccine and pregnancy. Why is itimportant? Safety and efficacy of thevaccineVacuna Tdap y embarazo. ¿Porque es importante su administración?. Seguridad y eficacia de la vacunaNamizato Ikemiyashiro, Claudia Sofia Namizato Ikemiyashiro, Claudia Sofia Whooping coughPertussisBordetella pertussisTdap vaccineMaternal vaccinationTos ferinaBordetella pertussisVacuna TdapVacunación en el embarazoPertussis (Bordetella pertussis) is a highly contagious respiratory disease that poses a significant threat to infants under six months of age, in whom clinical manifestations may be atypical and complications severe or fatal, including apnea, pneumonia, encephalopathy, and death. Despite the availability of effective vaccines for decades, pertussis continues to be a public health problem, with recurring epidemic cycles.Since the childhood vaccination schedule is not completed until six months of age, newborns and infants remain vulnerable. Tdap vaccination during pregnancy has been shown to be an effective and safe strategy for preventing the disease at this stage. Administering the vaccine between 20 and 36 weeks of gestation—preferably at least two weeks before delivery—ensures adequate transplacental transfer of antibodies, conferring passive protection to the newborn. Numerous observationalstudies and meta-analyses have shown significant reductions in hospitalizations, severe illness, and mortality in infants born to vaccinated mothers. Likewise, no significant maternal, obstetric, or neonatal risks have been observed. Nor has maternal vaccination been shown to clinically interfere with the infant's immune response after receiving their own vaccination schedule. Vaccination coverage among pregnant women in Peru is still suboptimal, highlighting the need for health personnel to commit to recommending and implementing this intervention in every pregnancy as an integral part of prenatal care.La tos ferina (Bordetella pertussis) es una enfermedad respiratoria altamente contagiosa que representa una amenaza significativa para los lactantes menores de seis meses, en quienes las manifestaciones clínicas pueden ser atípicas y las complicaciones graves o letales, incluyendo apnea, neumonía, encefalopatía y muerte. A pesar de la disponibilidad de vacunas eficaces desde hace décadas, la tos ferina continúa siendo un problema de salud pública, con ciclos epidémicos recurrentes. Dado que el esquema de vacunación infantil no se completa sino hasta los seis meses, los recién nacidos y lactantes permanecen vulnerables. La vacunación con Tdap durante el embarazo ha demostrado ser una estrategia eficaz y segura para prevenir la enfermedad en esta etapa. Al administrar la vacuna entre las semanas 20 y 36 de gestación —preferentemente al menos dos semanas antes del parto— se logra una adecuada transferencia transplacentaria de anticuerpos, confiriendo protección pasiva al neonato. Numerosos estudios observacionales y metaanálisis han evidenciado reducciones significativas en hospitalizaciones, enfermedad gravey mortalidad en lactantes nacidos de madres vacunadas. Asimismo, no se han observado riesgos significativos maternos, obstétricos ni neonatales relevantes.Tampoco se ha demostrado que la vacunación materna interfiera clínicamente con la respuesta inmunitaria del lactante tras recibir su propio esquema de vacunación.La cobertura vacunal en gestantes en el Perú aún es subóptima, lo que resalta la necesidad del compromiso del personal de salud para recomendar e implementar esta intervención en cada embarazo, como parte integral del cuidado prenatal.Sociedad Peruana de Obstetricia y Ginecología2025-11-13info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://ginecologiayobstetricia.pe/index.php/RPGO/article/view/277310.31403/rpgo.v71i2790The Peruvian Journal of Gynecology and Obstetrics ; Vol. 71 No. 2 (2025)Revista Peruana de Ginecología y Obstetricia; Vol. 71 Núm. 2 (2025)2304-51322304-512410.31403/rpgo.v71ireponame:Revista Peruana de Ginecología y Obstetriciainstname:Sociedad Peruana de Obstetricia y Ginecologíainstacron:SPOGspaenghttps://ginecologiayobstetricia.pe/index.php/RPGO/article/view/2773/3053https://ginecologiayobstetricia.pe/index.php/RPGO/article/view/2773/3054https://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessoai:ginecologiayobstetricia.pe:article/27732025-11-28T23:25:18Z
score 13.411838
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).